Management

Eric A. Adams, MIBS

Chief Executive Officer & President

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in

capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies.

He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Learn More

Dr. Sazzad Hossain, PhD, MSc

Chief Scientific Officer

Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery and natural health product development. His experience in phytochemistry and drug development served as the scientific foundation of InMed. As Group Leader and

Senior Scientist at Biotechnology Research Institute of National Research Council Canada, of the Canadian Government primary biotechnology research organization, he established a pharmacology laboratory to evaluate the safety and efficacy of new drugs under development for the treatment of cancer, cardiovascular and ocular diseases.

Prior to joining the National Research Council Canada, he served as Associate Director of Pharmacology at Xenon Pharmaceuticals in Vancouver, B.C., leading pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of The University of British Columbia. He served as Associate Professor of Pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996, and is the author of more than 40 peer-reviewed papers; primarily in the fields of pharmacology, genetics and nutritional sciences.
Learn More

Jeff Charpentier, CPA, CA

Chief Financial Officer

Mr. Charpentier is a respected veteran of more than 25 years in the biopharmaceutical sector. Mr. Charpentier has held a series of senior financial positions at a number of public and private companies in the pharmaceutical and technology sectors where he led multiple

equity financings.

Over his career, Mr. Charpentier has been instrumental in raising over $150M, and closing a number of corporate partnering/product sale transactions. He previously served as CFO for Lifebank Corp. (overseeing the successful sale of the company in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc.

Mr. Charpentier is a Certified Public Accountant, holds a Bachelor of Commerce Degree from the University of British Columbia and is a member of the Chartered Professional Accountants of B.C.
Learn More

Josh Blacher, MBA

Chief Business Officer

Mr. Blacher joined InMed Pharmaceuticals in 2018, bringing two decades of leadership experience in senior positions within the US healthcare and capital markets sectors, focusing primarily on strategic finance, business development, and managing relations with

the investment community.

Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences (NASDAQ:TRPX) and Galmed Pharmaceuticals (NASDAQ:GLMD). Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in Mergers & Acquisitions at Lehman Brothers.

Mr. Blacher holds an MBA in Finance from Columbia Business School.
Learn More

Alexandra D.J. Mancini, MSc

Senior Vice President, Clinical & Regulatory Affairs

Ms. Mancini has over 30 years of global biopharmaceutical R&D experience, overseeing a wide range of drug development activities, with a particular emphasis on clinical development and regulatory affairs. She has been an executive with numerous biotech

companies, including Snr. V.P. of Clinical & Regulatory Affairs at Sirius Genomics, where her responsibilities included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses.

Prior to joining Sirius Genomics, Ms. Mancini served as Sr. V.P. of Clinical & Regulatory Affairs at INMEX Pharmaceuticals; and V.P. of Regulatory Affairs at QLT Inc., where she played a significant role in the development of VISUDYNE from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anti-cancer drug PHOTOFRIN and its associated medical devices; the first drug-device combination product approved by the US Food and Drug Administration.

Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Learn More

Dr. Eric C. Hsu, PhD

Vice President, Pre-Clinical Research & Development

Dr. Hsu joined InMed with over 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affair and Operations.


His experience includes a wide array of activities, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines, and managing R&D budgets and timelines. Dr. Hsu is considered to be an expert in gene transfer and gene expression using vector systems.

Dr. Hsu received his Doctorate from the Department of Medical Biophysics at University of Toronto and his Bachelor’s degree from McGill University.
Learn More

Overview

Board of Directors

Scientific Advisory Board

Stay up to Date​

Subscribe to all of our investor information, including news, events, presentations and more